Renal cell carcinoma (RCC) is considered to be one of the most common types of kidney cancer in adults.

Kidney cancer can be challenging to study because it is biologically diverse and may remain undetected during its early stages.

At Bay Biosciences, we provide high-quality, clinical-grade Renal Cell Carcinoma Tissue Samples, Kidney Cancer Tissue Samples, and other important biospecimens for research and development purposes.

Tissue Samples, Serum, and Plasma in Renal Cell Carcinoma Research

Understanding Renal Cell Carcinoma

Renal cell carcinoma is a cancer that begins in the cells lining the small tubules of the kidney.

Researchers generally classify RCC according to its microscopic and molecular characteristics.

These are some common types.

Firstly, clear cell renal cell carcinoma (ccRCC. It is also the most common type of RCC.

Secondly, papillary renal cell carcinoma is another important subtype. It has distinct genetic and biological characteristics and is the second most common RCC subtype.

Thirdly, chromophobe renal cell carcinoma represents another recognized subtype with different microscopic features and molecular alterations.

Moreover, several less common RCC subtypes are also recognized. These include collecting duct carcinoma, mucinous tubular and spindle cell carcinoma, tubulocystic RCC, acquired cystic disease-associated RCC, and eosinophilic solid and cystic RCC.

Studying these subtypes requires access to well-characterized RCC Tissue Samples and associated clinical information.

Symptoms of Renal Cell Carcinoma

Renal cell carcinoma may not cause noticeable symptoms during its early stages. When symptoms do occur, they may include:

Many cases are also discovered incidentally during imaging tests performed for unrelated health conditions.

Causes and Risk Factors of Renal Cell Carcinoma

The exact cause of renal cell carcinoma is not always known.

However, several factors can increase the likelihood of developing kidney cancer

Firstly, smoking is an established risk factor.

Secondly, obesity may increase the risk of kidney cancer

Thirdly, high blood pressure has been associated with an increased risk.

Moreover, certain inherited genetic conditions such as sickle cell disease, tuberous sclerosis, and von Hippel-Lindau disease can increase susceptibility to RCC.

Diagnosis of Renal Cell Carcinoma

Healthcare providers use several tests to detect and evaluate suspected renal cell carcinoma.

Ultrasound

Ultrasound uses sound waves to produce images of the kidneys. It can help identify kidney masses and determine whether a mass appears cystic or solid.

Computed Tomography (CT) Scan

CT scans provide detailed cross-sectional images of the kidneys and surrounding structures. They can help determine the size and location of a tumor and whether it has spread to nearby structures. 

Magnetic Resonance Imaging (MRI)

MRI uses magnetic fields and radio waves to create detailed images of the kidneys and surrounding tissues. Doctors may use MRI when additional information is needed.

Biopsy

A biopsy involves removing a small amount of tissue for microscopic examination. Unlike many other cancers, kidney tumors do not always require a biopsy before treatment because imaging findings can sometimes provide sufficient information for clinical decision-making.

Treatment of Renal Cell Carcinoma

Treatment depends on the tumor stage, subtype, overall health, and whether the cancer has spread.

Treatment options may include:

Firstly, surgery is the main treatment for many patients with localized RCC.

Depending on the size and location of the tumor, surgeons may perform a partial nephrectomy, which removes the tumor while preserving part of the kidney, or a radical nephrectomy, which removes the entire kidney and surrounding tissues.

Partial nephrectomy can help preserve kidney function when it is technically appropriate.

Secondly, targeted therapy may be used, particularly for advanced or metastatic RCC.

These medicines target specific proteins and molecular pathways that help cancer cells grow and form new blood vessels.

Commonly used targeted therapies include tyrosine kinase inhibitors (TKIs) such as axitinib, cabozantinib, lenvatinib, pazopanib, and sunitinib.

Other targeted agents act on pathways such as mTOR.

Thirdly, immunotherapy has become an important treatment option for advanced RCC. Immune checkpoint inhibitors, including pembrolizumab, nivolumab, and ipilimumab, help the immune system recognize and attack cancer cells.

Some immunotherapy drugs are also used in combination with targeted therapies for advanced disease.

Moreover, combination treatment using immunotherapy and targeted therapies may be used for advanced disease.

Radiation therapy and other approaches may also be considered in selected situations.

RCC Tissue Samples and biospecimens remain important in treatment research because they allow investigators to evaluate potential predictive biomarkers and investigate why some tumors respond to treatment while others develop resistance.

The Importance of Renal Cell Carcinoma Tissue Samples in Research

Tumor tissue provides researchers with direct access to the biological material responsible for disease development.

Renal Cell Carcinoma Samples can support research into:

  • Histological classification
  • Tumor grade and stage
  • Genetic and molecular alterations
  • Tumor heterogeneity
  • Immune cell infiltration
  • Biomarker discovery
  • Drug discovery and development
  • Treatment response and resistance

Researchers may use Fresh Frozen Tissue Samples for molecular and genomic applications because rapid preservation can help maintain important biological characteristics.

Similarly, FFPE Tissue Samples can be examined through histological and immunohistochemical techniques to evaluate cellular and tissue characteristics.

Frequently Asked Questions

What is renal cell carcinoma?

Renal cell carcinoma (RCC) is the most common type of kidney cancer. It develops in the lining of the proximal tubules within the kidney.

What are renal cell carcinoma tissue samples used for?

Renal cell carcinoma tissue samples can help researchers study tumor histology, grade and stage, molecular mutations, immune cell infiltration, angiogenic signaling pathways, and tumor heterogeneity.

Why are serum samples important in renal cell carcinoma research?

Serum samples can support biomarker discovery, cytokine profiling, circulating tumor protein analysis, and autoantibody detection. Researchers can also use serum samples in longitudinal studies to monitor changes associated with disease progression or treatment response.

Why are plasma samples used in RCC research?

Plasma samples are useful for liquid biopsy research. Researchers can study circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and microRNAs to investigate potential biomarkers and tumor-related molecular changes.

Supporting Your Research With Bay Biosciences

At Bay Biosciences, we provide a wide range of Human Tumor Tissue Samples and other biospecimens from different therapeutic areas.

Our comprehensive collection of biospecimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.